You are here

Article info

Article menu
Download PDFPDF
Letter
Sequential interleukin-17/interleukin-23 inhibition in treatment-refractory psoriatic arthritis

Authors

  • David Simon Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Filippo Fagni Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Georg Schett Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Georg Schett, Rheumatology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany; georg.schett{at}uk-erlangen.de
View Full Text

Citation

Simon D, Fagni F, Schett G
Sequential interleukin-17/interleukin-23 inhibition in treatment-refractory psoriatic arthritis
Annals of the Rheumatic Diseases 2022;81:1334-1336.

Publication history

  • Received March 15, 2022
  • Accepted April 25, 2022
  • First published May 5, 2022.
Online issue publication 
August 11, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.